Global leader in home diagnostics and blood glucose monitoring selects clinivation enterprise solutions for accelerated global market access, scalable execution, and comprehensive global regulatory intelligence.
NATICK, MA – February 10, 2011 – Clinivation, Inc. is pleased to announce today that Nipro Diagnostics has selected clinivation enterprise solutions for accelerated market access, scalable execution, and comprehensive global regulatory intelligence.
The recent proliferation of new market clearance regulations and processes in the fast-growing international markets presents new challenges of execution: to effectively deliver larger, more complex market clearance portfolios faster than ever before.
In addition, ongoing industry consolidation means that global market clearance operations must now be capable of not only rapidly integrating new product lines and organizations- but also leveraging infrastructure for business growth and lean business performance.
And contemporary corporate governance now requires executives to implement effective market clearance operational controls to mitigate exposure from myriad compliance risks, penalties, fines, and legal costs.
To address the challenges of execution, the clinivation Global Platform enables cross-functional teams to work in scalable global market clearance operations that positions their organization to effectively address an expanded international scope.
Teams have full visibility on their consolidated global market clearance operations- and key performance metrics to find and fix the stall-outs and bottlenecks that trap revenue in inefficient process.
And teams can operate in new markets with access to knowledge and content that is far beyond that which is organic to any department, division, or business unit.
Intuitive dashboards, content unification technology, and streamlined reporting reclaim the team bandwidth that’s now consumed by functioning as a regulatory “help desk,” repeatedly reassembling product dossiers, blindly searching for documentation, and manually preparing routine status reports for senior management.
Enterprise-class systems reclaim the productivity that’s now consumed by the uncertainties of legacy “tracking tools,” home-grown databases, and spreadsheet farms. And integrated architecture accelerates workflow by enabling cross-functional teams to work in synchrony on parallel threads of activity in a manner that properly focuses, builds, and unifies their workflow into tangible, robust market clearance milestones.
For more information on the clinivation Enterprise Solution for On-Demand Global Regulatory Intelligence and Client-Directed Case Research Solutions, please visit the clinivation WorldView homepage.
For more information on the clinivation Enterprise Solution for Global Market Clearance Management, please visit the clinivation Global homepage.
About Nipro Diagnostics:
Nipro Diagnostics, Inc. is a wholly-owned subsidiary of Nipro Corporation, headquartered in Osaka, Japan. Nipro has been a world leader in providing medical products to the healthcare community for over 50 years. In addition to Nipro branded products, Nipro provides manufacturing support to some of the biggest names in the medical field.